Galderma's rosacea treatment Mirvaso set for EU approval
This article was originally published in Scrip
Following a nod from the US FDA in August, Galderma has received a positive opinion recommending the granting of a marketing authorization of Mirvaso (brimonidine tartrate 3 mg/g gel) from the EU's CHMP, for the symptomatic treatment of facial erythema of rosacea in adult patients.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.